Originally published In Press as doi:10.1074/jbc.M909883199 on March 28, 2000
J. Biol. Chem., Vol. 275, Issue 28, 21355-21363, July 14, 2000
Agonist-induced Isomerization in a Glutamate Receptor
Ligand-binding Domain
A KINETIC AND MUTAGENETIC ANALYSIS*
Rupert
Abele
§,
Kari
Keinänen¶, and
Dean R.
Madden
From the
Ion Channel Structure Research Group, Max
Planck Institute for Medical Research, Jahnstrasse 29, 69120 Heidelberg, Germany and the ¶ Viikki Biocenter, Department of
Biosciences, Division of Biochemistry, and the Institute of
Biotechnology, University of Helsinki,
FIN-00014 Helsinki, Finland
Received for publication, December 10, 1999, and in revised form, March 20, 2000
 |
ABSTRACT |
Agonist binding to glutamate receptor ion
channels occurs within an extracellular domain (S1S2) that retains
ligand affinity when expressed separately. S1S2 is homologous to
periplasmic binding proteins, and it has been proposed that a Venus
flytrap-style cleft closure triggers opening of glutamate receptor ion
channels. Here we compare the kinetics of S1S2-agonist binding to those of the periplasmic binding proteins and show that the reaction involves
an initial rapid association, followed by slower conformational changes
that stabilize the complex: "docking" followed by "locking." The motion detected here reflects the mechanism by which the energy of
glutamate binding is converted into protein conformational changes
within S1S2 alone. In the intact channel, these load-free conformational changes are harnessed and possibly modified as the
agonist binding reaction is used to drive channel opening and
subsequent desensitization. Using mutagenesis, key residues in each
step were identified, and their roles were interpreted in light of a
published S1S2 crystal structure. In contrast to the Venus flytrap
proposal, which focuses on motion between the two lobes as the readout
for agonist binding, we argue that smaller, localized conformational
rearrangements allow agonists to bridge the cleft, consistent
with published hydrodynamic measurements.
 |
INTRODUCTION |
Glutamate receptor ion channels
(GluR)1 play an essential
role in intercellular communication in the central nervous system (1-3). The functional channels are oligomeric assemblies of
100-kDa subunits that can be assigned to one of three
subfamilies:
-amino-3-hydroxy-5-methyl-4-isoxazole propionate
(AMPA), N-methyl-D-aspartate, and kainate
receptors (4). Following agonist binding, AMPA receptors induce
depolarization of the postsynaptic membrane on a millisecond time scale
(5), consistent with their role as the predominant mediators of fast excitatory synaptic transmission in the central nervous system (6).
Depending on the agonist and receptor subtype involved, the channels
then inactivate or desensitize (7-9), which is thought to be important
physiologically for avoiding prolonged excitation and for responding to
high frequency stimulation (10-13).
Mutagenesis experiments have located the GluR agonist-binding site in a
domain distant from the ion channel gate (14), as has also been
observed for the acetylcholine receptor (15). This implies that the
presence of agonist in the binding site is communicated to the channel
by means of conformational changes that propagate through the protein.
This coupling of the state of the pore to the conformation of the
agonist-binding site is reflected, for example, in different affinities
for the resting and desensitized states of various receptors (the
"binding-gating problem") (4, 16).
A ligand-binding domain identified within the GluR sequences has been
extensively characterized (17-21). It can be expressed as a soluble
fusion protein (S1S2) with a pharmacological profile similar to that of
the intact solubilized receptor, at least for AMPA receptor subunits
(17). Studies of S1S2-agonist binding can provide insight into
conformational changes within the domain, decoupled from the subsequent
rearrangements (i.e. channel gating and
desensitization) that they drive in the intact molecule. These changes
may reflect either stabilization of a pre-existing conformation or
induction of a novel conformation, although we speak here of their
being "driven" or "induced" by agonist binding for the sake of simplicity.
S1S2 is structurally related to the periplasmic binding proteins (PBP),
bacterial proteins that bind metabolites in the cleft between two
lobes. X-ray crystallography and solution scattering measurements on
PBP reveal that the ligand first docks against lobe I in the open cleft
and is then trapped by a dramatic cleft closure in the so-called
"Venus flytrap" mechanism (22-27). It has been suggested that a
similar lobe closure occurs in the ligand-binding domain of the GluR
and that this closure acts as the trigger for channel gating and/or
desensitization (19, 21, 28, 29). However, a dramatic lobe closure is
not strictly required for ligand binding even among PBP family members,
e.g. if the ligand can bridge the open cleft (30) or if
oligomerization constrains the conformational flexibility (31). We
suggest that both of these conditions may be fulfilled by GluR.
The crystallographic structure of an S1S2 domain core in complex with
kainate has provided a detailed snapshot of its interaction with a
ligand that induces unusually rapid (and weaker) desensitization in
AMPA receptors compared with glutamate or AMPA. As a result, whole-cell
currents induced by kainate appear non-desensitizing (32). This x-ray
structure has been interpreted as supporting a Venus flytrap mechanism
(21). We have pursued a parallel biophysical comparison of the bound
and free states of S1S2 to understand the nature and dynamics of the
conformational changes induced by the binding of different ligands. In
a first approach, we showed by solution scattering techniques that
there is no reduction in the radius of gyration of S1S2 upon agonist
binding, indicating that the magnitude of any conformational change in
the domain must be considerably smaller than for the PBP (33). Circular dichroism measurements confirm that there are no significant changes in
secondary structure content upon glutamate binding (34).
Here, we present an analysis of the affinity and kinetics of agonist
binding to S1S2 from the AMPA receptor GluRD, monitored using an
intrinsic tryptophan fluorescence signal and stopped-flow techniques.
These data provide the first biophysical evidence that S1S2-agonist
binding is a two-step process, in which docking is followed by
isomerization. This isomerization represents the conversion of the free
energy of agonist binding into mechanical changes by S1S2 alone,
i.e. in the absence of load. Comparison with the (possibly
distinct) S1S2 conformational changes that occur in the context of the
intact receptor should ultimately provide insight into the mechanism by
which agonist binding drives channel activation and desensitization. By
analyzing the agonist binding kinetics of a panel of site-directed
mutants, we have identified key side chains in the docking and locking
steps. Our data also complement the recent finding that the
phosphate-binding protein engages in rapid docking and subsequent slow
cleft closure (35). This is in contrast to the earlier proposal of
rapid isomerization for the arabinose-binding protein (36) and suggests
that S1S2 and the PBP have similar kinetic profiles.
 |
EXPERIMENTAL PROCEDURES |
Protein Expression and Purification--
S1S2 from GluRD was
prepared as described (17) with modifications (37). The panel of
site-directed mutants has also been described (38).
Fluorescence Titration--
All fluorescence spectra and
titrations were measured with an SLM-AMINCO 8000 spectrofluorometer.
The excitation band pass was 4 nm; the emission band pass was 8 nm; and
the sample cell was maintained at 5 °C with a circulating water
bath. All measurements were determined as the ratio between the
fluorescence change of the sample and a reference cuvette filled with
rhodamine to reduce the noise due to intensity fluctuations of the
xenon lamp. The excitation wavelength was 280 nm for all measurements,
and the fluorescence change of the titration measurements was followed at 336 nm. For the titration experiments, aliquots of 10 µl of concentrated ligand were added to a quartz cuvette containing 3 ml of
protein (0.03-0.50 µM) in 10 mM
NaPi (pH 7.3) and mixed continuously with a magnetic
stirrer. For the titration measurements with AMPA, 100 mM
KSCN, 2.5 mM CaCl2, and 30 mM Tris
(pH 7.2) was used for comparability with published measurements. Data
points were collected every 3 s. For each ligand concentration,
20-25 data points were averaged. The fluorescence change was corrected for the dilution of the sample with ligand. The results were fitted by
Equation 1,
|
(Eq. 1)
|
where Fi is the fluorescence observed after
the ith addition of ligand, F0 is the
fluorescence of the free protein, P0 is the total protein
concentration, and L0 is the total ligand concentration.
Free parameters were the dissociation constant Kd
and the maximum fluorescence change in going from unbound to completely
bound protein (
Fmax). Due to kainate
absorbance at 280 nm at high concentrations, Equation 1 was modified to
include an additional component linear in ligand concentration
(L0) for mutants E403Q and E706D, which had a very low
affinity for kainate. Hill coefficients calculated for the binding
reactions were between 0.9 and 1.1 (±0.05) for glutamate and kainate
and slightly higher (1.0-1.5) for AMPA.
Stopped-flow Kinetics--
Rapid kinetic measurements were
performed in an SF-61 stopped-flow fluorometer (Hi-Tech Scientific).
The excitation wavelength was 280 nm, and the fluorescence decrease was
detected with a photomultiplier with a WG-320 filter (nominal cutoff of
320 nm). The dead time of the device was 1.0-1.5 ms. For glutamate and kainate, the kinetic measurements were performed in 10 mM
NaPi (pH 7.3), and for AMPA, in 100 mM KSCN,
2.5 mM CaCl2, and 30 mM Tris (pH
7.2), again for purposes of comparability with published data. Control
experiments were also performed with AMPA in which 100 mM
KCl replaced 100 mM KSCN. All measurements were carried out
at 5 °C with a protein concentration between 0.05 and 5 µM. Pseudo first-order reaction conditions were employed
(ligand concentration >5-fold higher than protein concentration). To
improve the signal-to-noise ratio, five to seven individual traces for
each ligand concentration were averaged. The measurements were repeated
two to three times.
The reactions were monophasic for glutamate and kainate binding to all
S1S2 variants; these time courses were fitted with a single exponential
curve. For AMPA binding, a biphasic reaction was observed, of which one
phase (kobs
0.6-1.2
s
1) was independent of added ligand and was
thus apparently a mixing artifact caused by the presence of the
chaotrope KSCN (monophasic reactions were observed when KCl
replaced KSCN in the binding buffer). For AMPA concentrations above 10 µM, the contribution of the second phase could be ignored
due to the rapid time course of the reactions, and the data were fitted
with a single exponential curve. For lower concentrations, a
biexponential fit was performed, but only the
ligand-dependent time constant was considered.
Standard kinetic analysis was performed as described (39). For
agonist/protein combinations showing a linear dependence of
kobs on ligand concentration under pseudo
first-order conditions, a one-step mechanism was assumed (see Equation 4 below). A least-squares linear fit was performed according to
Equation 2,
|
(Eq. 2)
|
where
is the concentration of free ligand. For
agonist/protein combinations showing a nonlinear dependence of
kobs on ligand concentration under pseudo
first-order conditions, a two-step binding mechanism was assumed (see
Equation 5 below) in which association is rapid compared with
isomerization (see Equation 6 below). A nonlinear least-squares fit was
performed according to Equation 3.
|
(Eq. 3)
|
Modeling--
The interactions of glutamate with the S1S2
binding site (see Fig. 4B) were modeled by assuming that the
glutamate atoms would adopt the same positions as corresponding atoms
in kainate (e.g. glutamate
-amino = kainate
pyrrolidine nitrogen;
-carboxylate = 2-carboxylate;
-carboxylate = 3-methyl carboxylate). Ligand interactions were
plotted using the program LIGPLOT (40). Modeling of S1S2 side chain
mutations was performed in O (41) using standard side chain rotamers
(42).
 |
RESULTS |
S1S2-Ligand Binding Induces a Conformational Change--
The
intrinsic fluorescence of S1S2 changed upon agonist binding (Fig.
1). Two facts suggest that Trp is the
primary internal fluorophore, both for the intrinsic fluorescence and
for the agonist-induced fluorescence change. The observed excitation
maximum lies between 282 and 283 nm for the apo and holo forms of S1S2
and for the difference spectrum (emission monitored at 336 nm).
Furthermore, using excitation wavelengths of 280 and 296 nm, similar
emission spectra were obtained, although 296 nm excitation produced a
weaker signal (at 336 nm, emission was ~16% of that seen at 280 nm;
excitation at 290 nm yielded ~50%). None of the four S1S2
tryptophans is located in the immediate vicinity of the binding site
(21), so this signal most likely reflects an isomerization process. Together with the nonlinear kinetic results presented below, this represents the first direct evidence that the S1S2 domain by itself undergoes a conformational change following ligand binding.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
Fluorescence titrations of wild-type S1S2
binding to glutamate (circles), kainate
(squares), and AMPA (triangles) at
5 °C, shown together with curves fit for a single binding site using
Equation 1. The affinities thus determined are shown in Table II.
To accommodate the wide range of ligand concentrations, a semilog plot
was used.
|
|
Kainate produces apparently non-desensitizing whole-cell currents at
AMPA receptors due to its rapid desensitization kinetics (32), and it
has thus been proposed that the kainate-bound x-ray structure reflects
a non-desensitized, activated state intermediate between the resting
and desensitized states (21). Here, we observed that the maximum
fluorescence change (
Fmax, Equation 1)
observed in the presence of saturating concentrations of agonist was
smaller for kainate (
10.8 ± 3.8%) than for glutamate
(
19.0 ± 1.2%) or AMPA (
17.0 ± 1.3%). Although we
cannot assign the conformational changes in S1S2 to functional states
of the intact receptor, it is possible that the more rapid and partial
desensitization induced by kainate reflects smaller induced
conformational changes in the domain.
Since we do not know which tryptophan residue(s) contribute to the
signal, it is not possible to interpret the fluorescence change
directly in structural terms. However, the fluorescence change
permitted us to measure the kinetics of protein-ligand association
following rapid mixing. In addition, comparison of the kinetics of
wild-type S1S2 and site-directed mutants enabled us to assess
structural changes associated with the initial steps of ligand binding.
The kinetic behavior of protein-agonist binding was monophasic, rapid,
and concentration-dependent over a wide range of agonist concentrations (Fig. 2). Under pseudo
first-order conditions, the apparent rate constants
(kobs) for AMPA and glutamate showed a linear
dependence on ligand concentration (Fig. 2D), yielding estimates (Table I) for overall
association (kon) and dissociation (koff) rate constants analogous to values
determined for a number of PBP for a one-step binding mechanism (36,
43, 44) (Equation 4),
|
(Eq. 4)
|
where P is S1S2 and L is agonist.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetics of wild-type S1S2-agonist
binding. A and B, stopped-flow time courses
obtained for glutamate (2.5 µM) and kainate (3 µM) and for AMPA (10 µM) binding,
respectively, to wild-type S1S2 under pseudo first-order conditions at
5 °C. C, stopped-flow time courses obtained for glutamate
binding to wild-type S1S2 under pseudo first-order conditions at
5 °C at four different glutamate concentrations. Single exponential
fits are superimposed on the experimental data. D,
concentration dependence of the pseudo first-order rate constants for
association of AMPA (triangles), kainate
(squares), and glutamate (circles) with wild-type
S1S2 as determined by stopped-flow measurements. The curves
show linear fits for glutamate (solid line) and AMPA
(finely dashed line) binding and a hyperbolic fit for
kainate binding (coarsely dashed line). The concentration
dependence of kobs for AMPA remains linear to
the resolution limit of our apparatus (~600
s 1 at 300 µM AMPA).
|
|
The rate constants thus obtained for glutamate are similar to those of
PBP specific for various amino acids and sugars, with a rapid, but not
necessarily diffusion-limited, kon on the order of 107 to 108
M
1 s
1
(here, 1.6 × 107
M
1 s
1)
and a slow koff on the order of 1-10
s
1 (here, 7.6 s
1).
This slow glutamate dissociation rate constant also agrees broadly with
values obtained by modeling electrophysiological data: rate constants
for quisqualate and domoate dissociation from AMPA receptors have been
estimated at 30-37 s
1 (45), and those for
glycine dissociation from N-methyl-D-aspartate receptors at 0.3-1.3 s
1 (46). The
dissociation rate constant for AMPA is significantly slower than that
for glutamate: 0.06 s
1. This is also
consistent with an estimate of 0.032 s
1 for
AMPA dissociation from rat brain membranes (47). When KSCN was replaced
by KCl in the AMPA binding buffer, a linear concentration dependence of
kobs was also observed; consistent with
observations on intact receptors, the main effect of KSCN is to
stabilize the ligand-bound form, i.e. to reduce
koff (34, 47).
Unfortunately, a more detailed comparison of the kinetics of S1S2- and
GluR-ligand binding is precluded by the paucity of experimental results
on the intact molecule. This is due to limitations in the speed of
agonist application in electrophysiological experiments and to
difficulties expressing and purifying sufficient quantities of GluR for
biochemical measurements. Flash photolysis techniques (48) and the
large-scale expression of recombinant intact
GluR2 may permit more
detailed comparison in the future.
Unlike the AMPA and glutamate values, the pseudo first-order rate
constants for kainate show a hyperbolic dependence on ligand concentration (Fig. 2D). This is not consistent with a
one-step binding mechanism, nor is it consistent with a Venus flytrap
mechanism in which the cleft closure step is faster than the initial
binding step, as has been proposed for the arabinose-binding protein
(36). It would, however, be consistent with a two-step dock/lock
mechanism (Equation 5),
|
(Eq. 5)
|
in which P is S1S2 in its unbound conformation, P* is S1S2
following isomerization, and the transition from P to P* produces the
fluorescence signal, provided that binding is more rapid than isomerization, i.e. (Equation 6),
|
(Eq. 6)
|
where
and
are the equilibrium concentrations of
free S1S2 and agonist, respectively (39). In this case, we can estimate the equilibrium dissociation constant for docking
(Kd1) and the forward and backward
isomerization rate constants (k+2 and
k
2) for the reaction with kainate
(Table I). Such slow isomerization was recently demonstrated for the
phosphate-binding protein (35). The hyperbolic concentration dependence
of kobs for S1S2 also supports the observation
that the reporter Trp residue(s) must be distant from the binding site
and therefore sensitive to the isomerization, rather than the docking, step.
Consistent with slow isomerization in S1S2, kinetic measurements on
hippocampal neurons using caged kainate reveal that channel opening
occurs more slowly than agonist binding (48). These measurements also
yielded forward and backward rate constants of activation for intact
AMPA receptors of 5000 and 640 s
1,
respectively, faster than the values detected here for S1S2 (Table I).
This difference may indicate that free S1S2 is passing beyond a state
corresponding to the open state to one corresponding to the
desensitized state. Alternatively, coupling of the S1S2 changes to
other conformational changes occurring in the intact receptor may speed
these processes in vivo.
Residual Affinity of Arg486 and Glu706
Mutants--
To further characterize the ligand-binding mechanism and
to attempt to understand the different shapes of the kainate
(hyperbolic) and glutamate (linear) kobs binding
curves, we also studied a panel of 10 S1S2 site-directed mutants (Table
II; see note on residue numbering) (38).
The selection of candidate residues was greatly facilitated by
extensive preceding mutagenesis of the S1S2 domain, allowing us to
focus on residues known to affect binding affinity and/or channel
gating properties (38). Fluorescence titrations were performed on the
mutants (Table II) to select suitable mutants for kinetic analysis and
to provide a reference affinity measurement for comparison with that
calculated from the kinetic data. All of the mutants tested showed an
intrinsic fluorescence change upon agonist binding, with the exception
of E706Q, for which no fluorescence change could be detected up to 0.4 mM AMPA or 23 mM glutamate. It is possible that
E706Q retains a residual affinity for agonists, but fails to undergo
isomerization and therefore exhibits no fluorescence change upon
binding. E706Q was also poorly expressed in several experiments, which
may indicate that this mutation fundamentally destabilizes the protein.
The fluorescence titration curves for all three agonists binding
wild-type S1S2 could be fit with a hyperbolic curve for a single
binding site (Fig. 1). The same was true for all S1S2 mutants, with the exception of the very weak kainate binders E403Q and E706Q, which required correction for kainate absorbance at 280 nm (data not shown).
View this table:
[in this window]
[in a new window]
|
Table II
Equilibrium dissociation constants of S1S2 mutants
Equilibrium constants were determined by least-squares fits to
fluorescence titration data (see Equation 1 under "Experimental
Procedures").
|
|
Strikingly, the greater sensitivity of this technique compared with
filter binding made it possible to detect weak binding of both AMPA and
glutamate to the mutant R486K, which has been reported to abrogate both
agonist binding and channel function (28, 38, 49-52) and which has
been termed an "absolute requirement for the acquisition of
ligand-binding activity" by GluRA (53). The affinity for glutamate
was weakened by only 900-fold, whereas that for AMPA was reduced by
>20,000-fold (Table II). The mutation E706A, for which neither binding
nor channel activation has been detected previously (29, 38, 50), also
was shown to have a weak residual affinity for glutamate and AMPA
(Table II), reduced 40,000- and 25,000-fold, respectively. In the
kainate·S1S2 core complex, Arg486 and Glu706
are responsible for binding the homologs of the
-carboxyl and
-amino moieties shared by most GluR agonists (21), as had been proposed based on their importance for ligand binding affinity (38). To
further characterize the importance of the ligand's
-amino group,
we also assessed the affinity of wild-type S1S2 for glutaric acid,
which is identical to glutamate except for the absence of an
-amino
group; using fluorescence titration, no binding could be detected up to
a ligand concentration of 7.8 mM.
The effects of the other mutants on ligand affinities did not show
significant deviations from those observed using filter binding studies
(38), although in some cases, detailed comparisons were limited by
large standard deviations. In two cases, apparent differences were
clearly affected by technical limitations. Y451F showed a clearly
reduced affinity for glutamate by fluorescence titration (Table II),
whereas competition binding data revealed no change (38). Although
reproducible, the filter binding data may have been compromised by the
15-fold reduced affinity of Y451F for the reporter ligand AMPA and/or
by an increase in the dissociation constant for AMPA (nearly 8-fold).
The affinity of AMPA for mutant E706D appeared to increase
significantly according to filter binding studies, whereas fluorescence
titration revealed no obvious shift. Given such tight binding, the
equilibrium dissociation constant calculated by fluorescence titration
is necessarily imprecise (since the minimum protein concentration
required to obtain a signal is large relative to Kd)
and represents only an upper limit. In this case, the filter binding
data are likely to be more accurate due to the much lower protein
concentration required. In general, however, the fluorescence data are
more accurate than those determined by filter binding techniques for glutamate and kainate. Overall, the fluorescence data also reproduce the results of mutagenesis studies on agonist binding and
electrophysiology (e.g. Refs. 29, 49, and 50).
Mutants Isomerize Slowly after Binding Glutamate--
Stopped-flow
measurements were performed with seven mutants, each of which had shown
an altered ligand affinity profile as judged by fluorescence titration.
Of these, kinetics could not be followed by the stopped-flow technique
for R486K binding to any ligand, for E706A binding to glutamate or
kainate, or for E706D binding to kainate, presumably due to the extreme
destabilization of the resulting complexes (see below). Six mutants,
affecting four side chains, proved suitable for kinetic analysis (Fig.
3 and Table I). As for the wild-type
protein, each mutant showed a single relevant,
concentration-dependent time constant of fluorescence change per agonist concentration. As would be expected, the affinities calculated from the measured kinetic parameters (Table I) are in good
agreement with those measured by fluorescence titration (Table II).
Differences were observed for E403D binding to kainate and AMPA, but
these are most likely due to technical difficulties in the kinetic
measurement of extremely small k
2
values, which are reflected in the large standard deviations.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Concentration dependence of the pseudo
first-order rate constants for agonist binding to S1S2 mutants.
The symbols and fitted curves are as described in the legend to Fig.
1B. Note the different ranges for ligand concentrations
necessary to resolve the data for different mutants.
|
|
For all six mutants, the concentration dependence of the pseudo
first-order rate constant was linear for AMPA, as it had been for the
wild-type protein. A hyperbolic dependence was observed for three of
four mutants whose binding to kainate could be followed kinetically,
again consistent with the wild-type observations; K450H showed a linear
dependence suggestive of a sharp increase in
k+2. Unlike the wild-type protein, all five
mutants whose binding to glutamate could be followed (E403D, E403Q,
K450H, Y451F, and E706D) exhibited a nonlinear dependence of the pseudo
first-order rate constant on glutamate concentration. This strongly
suggests that these mutants bind glutamate in a two-step process, in
which a rapid "docking" of protein and ligand is followed by a
slower "locking" isomerization. In addition, this analysis
permitted us to identify the contribution of individual side chains to
each process.
Docking--
Mutations in two side chains, Glu403 and
Tyr451, clearly affected
Kd1, i.e. the affinity of the
binding site for ligand in the initial, docking step (Table I). Both
are located in lobe I, suggesting that the initial complex is formed
here, in analogy to the PBP (26). For kainate, E403Q and Y451F both
increased Kd1 relative to the wild type,
whereas E403D did not. For glutamate,
Kd1 could not be determined for
wild-type S1S2. However, as observed for kainate, E403Q increased
Kd1 relative to E403D. Y451F did not.
In the structure of the S1S2 core bound to kainate, Glu403
does not contact kainate directly. Instead, it forms a hydrogen bond via a water molecule to Tyr451 (Fig.
4A) (21). Working from this
structure, we found that a standard rotamer of Asp403 could
form a direct hydrogen bond to Tyr451 in its wild-type
conformation, possibly accounting for the lack of disruption observed
in E403D versus wild-type binding of kainate. Thus, the
E403D value may act as a surrogate for the
Kd1 for wild-type binding of glutamate,
which cannot be measured directly. However, Gln403, which
disrupted kainate docking relative to the wild type and glutamate
docking relative to E403D (Table I), should be able to form the same
hydrogen-bonding network with Tyr451 as Glu403.
Thus, it appears that for this residue, the negative charge, rather
than the water-mediated hydrogen bond to Tyr451, may be
important for the docking step. Curiously, E403A shows wild-type
affinity for AMPA and glutamate (38); however, in the absence of
kinetic measurements, it is possible that compensating changes in the
locking equilibrium mask changes in docking affinity or vice
versa.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Schematic representation of selected hydrogen
bond and hydrophobic interactions between ligand and binding protein
for the S1S2 core domain with kainate (21) (A), a
model of the S1S2 core domain with glutamate (B), and
QBP with glutamine (58) (C). The ligand is shown as a
ball-and-stick figure. Binding protein residues are shown as stick
figures with bonds colored by atom type: black, carbon;
red, oxygen; and blue, nitrogen. Residues from
lobe I are clustered above and to the right of the ligands
(Arg486, Thr481, Pro479,
Tyr451, and Glu403 for S1S2; Arg75,
Thr70, Gly68, Phe13, and
Phe50 for QBP). Residues from lobe II are clustered below
and to the left of the ligand (Glu706, Thr656,
and Ser655 for S1S2; Asp157 for QBP). The
three-way hydrogen-bonding network discussed under "Results" is
highlighted (red bond distances). Although the binding site
is distorted by the projection algorithm, the relative orientations of
the ligands approximately reflect those found in three dimensions,
e.g. by superposition of secondary structure elements of
lobe I. The hinge axis runs approximately horizontal.
|
|
Tyr451 engages in van der Waals interactions with the
isopropenyl group of bound kainate (Fig. 4A). If glutamate
binds S1S2 with its carboxyl and amino groups in the same positions as
those of kainate, then there would be no interaction between glutamate and Tyr451 (Fig. 4B). Consistent with this
model, Y451F increased the Kd1 for
kainate, but probably not that for glutamate; the indirect hydrogen
bond to Glu403 presumably constrains Tyr451 to
a conformation that does not interfere with the volume occupied by
bound kainate. Cast free, Phe451 could transiently block
the kainate, but not the smaller glutamate-binding site. In any case,
it is unlikely that Tyr451 contacts bound glutamate
directly, which would require a substantial cleft closure or side
chain rearrangement relative to the kainate structure (21).
The linear kobs versus ligand
concentration curves for AMPA lie below and to the right of hyperbolic
curves for kainate binding to wild-type S1S2 and for glutamate and
kainate binding to all mutants but one (Fig. 3). Since no curvature was
detected for AMPA, it appears that the docking affinity
Kd1 of AMPA is substantially weaker than
those of glutamate and kainate. For E403Q binding, the AMPA line lies
above the other curves; in this case and in the comparison of glutamate
and AMPA binding by wild-type S1S2, no information is available about
relative Kd1 values. The rate constants
reveal that high affinity binding of AMPA (Table II;
Kd 60-fold tighter than for glutamate) is due
instead to the exceptional stability of the complex once formed. The
overall dissociation rate constant (koff) is
190-fold slower than that for glutamate (Table I). This may be due to the expected ability of the side chain isoxazole moiety to form more
extensive interactions with lobe II than kainate or glutamate (21). The
high stability of the AMPA·S1S2 complex is consistent with its
suitability for filter binding experiments.
Locking--
Two Glu706 mutants, E706D and E706A,
strongly affected the backward rate constant of isomerization
(k
2), i.e. the speed of
"unlocking", without apparently affecting docking affinity. For
AMPA, k
2 was increased 7-fold in
E706D and >2000-fold in E706A (Table I). For glutamate,
k
2 was increased 18-fold in E706D.
Agonist binding could not be followed by stopped-flow techniques for
glutamate binding to E706A and for kainate binding to both mutants,
even though fluorescence titration measurements revealed (weak) ligand
binding for glutamate to E706A and for kainate to E706D. A likely
explanation is that the weak affinity also reflects a sharp increase in
k
2, which is the minimum rate that
can be observed: if k
2
500 s
1, the time course will be inaccessible to
our stopped-flow device since kobs
k
2 (Equation 3). E706Q, for which
no binding could be detected even by titration experiments, may have an
even higher value for k
2.
Alternatively, it may not isomerize upon agonist binding, so no
fluorescence signal can be detected. In the one Glu706
mutant for which Kd1 and
k+2 could be estimated (glutamate binding to
E706D), neither the equilibrium dissociation constant for docking nor
the forward isomerization rate constant was significantly destabilized
relative to other mutants. Thus, it appears that Glu706 is
essential for stabilizing the "locked" conformation, rather than
for docking. In addition, it appears that a negative charge is essential.
In complex with kainate, Glu706 binds the pyrrolidine
nitrogen (21), which presumably corresponds to the
-amino group in
glutamate. The amino group also forms hydrogen bonds to the carbonyl
group of Pro479 and to the side chain of
Thr481, which in turn is hydrogen-bonded to
Glu706 (Fig. 4, A and B; hydrogen
bonding distances shown in red). The three-way
hydrogen-bonding network of Thr481, Glu706, and
the agonist amino group, in which each component binds the other two,
thus knits together the two lobes of the protein and the agonist. The
nearly tetrahedral geometry of the hydrogen bonds formed by the
ligand's nitrogen atom is well suited to the
-amino moiety of the
physiological ligand.
Lys450 may play a secondary role in the locking process. In
the kainate structure, Lys450 is located at the periphery
of the binding site, does not interact directly with the agonist, and
is distant from any potential "hinge" positions. However, it has
been proposed that following further cleft closure, Lys450
could stabilize glutamate binding by reaching across the lip of the
cleft to bind Asp652 or Ser653. Thus, it should
be a locking residue for glutamate, but not kainate (21). It is
therefore surprising that the K450H mutation affected both
k+2 and k
2
for kainate (Table I). The forward rate constant
(k+2) appeared to have increased significantly relative to the wild type since this mutant showed a linear dependence of kobs on ligand concentration for kainate,
whereas the wild-type dependence was hyperbolic (Figs. 2D
and 3; see "Discussion"). The backward rate constant
(k
2) actually decreased,
i.e. the K450H substitution stabilized the locked
conformation of the kainate complex. In contrast to the unexpected
results with kainate, the effect of the mutation K450H on glutamate
binding is consistent with a proposed role in stabilizing the locked
conformation of the glutamate complex (21). K450H increased
k
2 for glutamate 5-fold and
apparently decreased k+2 since the linear
kobs dependence of the wild type was replaced by
a nonlinear dependence in the mutant (Figs. 2D and 3; see
"Discussion").
 |
DISCUSSION |
The Motor That Drives GluR--
Interpreted in terms of the
structure of the kainate-bound S1S2 core (21), these data suggest a
first picture of the sequence of interactions between agonist and the
GluR ligand-binding domain. Agonists dock to lobe I of S1S2 adjacent to
a ridge formed by side chains Glu403 and
Tyr451. Following relatively rapid docking, the binding
site then undergoes a slower isomerization that leads to formation of a
stable high affinity complex. A three-way hydrogen-bonding network
involving the agonist amino moiety and the side chains
Thr481 on lobe I and Glu706 on lobe II appears
to play a key role in locking the agonist in.
Of course, our data apply to the S1S2 ligand-binding domain alone,
acting outside the context of the intact receptor. In the absence of
intact GluR structures, it is impossible to establish whether its
agonist-bound conformation corresponds closely to that of the domain in
the open or desensitized GluR (or neither) since these states have
meaning only for a functional ion channel. The high affinity of
isolated S1S2 for agonists is reminiscent of values reported for
inhibition constants rather than EC50 values (4),
suggesting that agonist-bound ("holo-") S1S2 may be more similar to
the desensitized state than to the open state of GluR. However,
holo-S1S2 may instead approximate the open state. In this case, the
discrepancy between the Kd values of S1S2 and the
EC50 values of GluR would reflect S1S2's uncoupling of agonist binding from the energetically unfavorable process of channel opening.
Given this ambiguity, we prefer not to attempt to assign holo-S1S2 to a
specific functional state. Instead, we wish to emphasize that the
motions undergone by S1S2 on its own represent the fundamental molecular process that converts agonist-binding energy into
conformational changes. These changes are presumably harnessed to drive
channel gating and/or subsequent desensitization in the intact receptor.
Despite this ambiguity, Glu706 and Thr481 may
play an important role in channel gating. Mutations to alanine of the
Glu706 homologs in NR2A (Asp731) and NR2B
(Asp732) and of the Thr481 homolog in GluRA
(Thr476) abolish channel activity (29, 54). Thus, we
propose that recruitment of Glu706 and Thr481
into a hydrogen-bonding network with agonist could well be a key step
in channel gating. On the other hand or in addition, it is possible
that these mutations operate indirectly on the EC50 values,
via changes in the desensitized state(s) of the molecule. A test of
these alternatives would be provided by an analysis of antagonist
binding to appropriately mutated intact GluR channels. Due to UV
absorption by the antagonist compounds, fluorescence binding studies
are, however, not feasible.
The foregoing proposal does not exclude the possibility that the
holo-S1S2 end state may have similarity to the desensitized conformation. This is suggested by two observations. First, the kinetics we observed for S1S2 binding of kainate are slower than those
determined by flash photolysis for kainate activation of GluR (48).
Second, the rapid and partial desensitization induced by kainate (32)
corresponds qualitatively to the observation that kainate induces a
smaller fluorescence change in S1S2 than do glutamate and AMPA. As
mentioned above, however, a detailed comparison of S1S2 and GluR
structures in defined states will ultimately be required to determine
the functional correlates of the apo and holo forms of S1S2.
Comparison of PBP and S1S2 Kinetics--
Qualitatively, two types
of kinetic behavior were observed for the binding of agonists to S1S2.
Wild-type S1S2 bound AMPA and glutamate with an observed rate constant
that increased linearly with increasing agonist concentration. The same
linear dependence was observed for AMPA binding to all S1S2 mutants
studied here and for kainate binding to K450H. In contrast, a
hyperbolic dependence of kobs on agonist
concentration was observed for glutamate binding to all S1S2 mutants
studied and for kainate binding to wild-type and all mutant S1S2
molecules but one.
What explains the different dependence of kobs
on agonist concentration? We propose that isomerization is slower than
binding for all three agonists binding to all S1S2 molecules, but that large k+2 values make it impossible to detect
hyperbolic behavior in some cases due to the limited temporal
resolution of the stopped-flow apparatus. Significant departure from
linearity is observed only for values of kobs
approaching (2k
2 + k+2)/2. Since the resolution of our stopped-flow
device is roughly 500 s
1, saturation behavior
is inaccessible for reactions with k+2
1000 s
1, and the smallest value of
k+2 we detected was 850 s
1 (Table I). If the values for glutamate
binding of wild-type S1S2 or for kainate binding of K450H were only
severalfold higher, then our experiments could measure only the
initial, linear phase of the hyperbolic curve. Unfortunately, attempts
to surmount the kinetic limitation for S1S2 using faster pressure- or
temperature-jump experiments were not technically feasible
(34).3
If this hypothesis is correct, one effect of the mutations would be to
reduce k+2 sufficiently to bring the saturation regime within experimental reach, say by an order of magnitude or less.
This is consistent with the relatively modest shifts in
k+2 seen for kainate binding (Table I).
Calculations with Kd1 = 1 mM
and k+2 = 2 × 104
s
1 (k
2 = 7.6 s
1) yield kinetic behavior consistent
with that shown in Fig. 2D for glutamate binding to
wild-type S1S2. Assuming additionally that k+1
is
108 M
1
s
1, locking would indeed be slower than
docking for wild-type S1S2 binding of glutamate at physiological concentrations.
The same technical limitation most likely also affected earlier
measurements of PBP-ligand binding kinetics. A linear concentration dependence of kobs for the arabinose-binding
protein had been interpreted as showing that isomerization is faster
than initial docking (36). However, recent stopped-flow measurements on
a Trp mutant of the phosphate-binding protein revealed a hyperbolic dependence of kobs; the mutant protein was shown
to have wild-type phosphate affinity, and the introduced reporter
Trp side chain was shown crystallographically to be distant from the
bound phosphate (35). These data were interpreted in terms of nearly
diffusion-limited docking and relatively slow isomerization. Slow
isomerization has also been detected for the dicarboxylate-binding
protein DctP, although this protein preferentially adopts the closed
conformation in the absence of ligand and therefore must additionally
open before binding ligand, in contrast to the other PBP
studied (55).
It seems likely that the linear concentration dependence of
kobs seen for the arabinose-binding protein
simply represents the initial (linear) phase of a hyperbolic curve, as
it probably does when observed for S1S2. This interpretation is also
consistent with the fact that the maximal ligand concentrations used in
kinetic studies of the arabinose-binding protein (100 µM)
probably did not approach Kd1, the point
at which significant curvature would be observed (36, 44). Electron
density peaks from ligands soaked into crystals of the open form of the
leucine/isoleucine/valine-binding protein did not show saturation at
concentrations as high as 10-50 mM, i.e. >2
orders of magnitude higher (56). According to this proposal, all PBP
would share a common kinetic motif with the GluR: rapid docking
followed by slow locking.
A Subtler Flytrap--
Despite the overall kinetic and structural
similarities between S1S2 and the PBP, solution scattering data show
that S1S2-agonist binding does not induce a large lobe closure
equivalent to that seen for the PBP (33). Thus, instead of focusing on
gross shifts between the lobes, as suggested by the Venus flytrap
analogy, it is likely that smaller structural shifts within S1S2 will
prove sufficient for inducing activation and desensitization. However, previous mutagenesis data (e.g. Refs. 29, 38, 49, and 50) and our kinetic results have identified residues on both sides of the
cleft that interact with agonist. Interestingly, in S1S2, agonists are
apparently able to interact with both lobes even in the absence of a
dramatic relative motion due to an important structural difference
between the orientations of ligands bound to S1S2 and the PBP. Here,
for the first time, we can also assign an order of interaction to
certain side chains involved in the binding process.
The homologs of Glu403 and Tyr451 sandwich the
ligand side chain in a variety of amino acid-binding PBP, including the
glutamine-binding protein (QBP) that is most closely related to the
S1S2 core (Fig. 4C) (21, 25, 57, 58). PBP-bound amino acids
thus lie roughly parallel to the hinge of the cleft (i.e.
roughly horizontal in Fig. 4C). In contrast, in the
kainate·S1S2 complex, the kainate "side chain" is directed almost
at right angles to this orientation, brushing past Tyr451
as its terminal carboxyl methyl group interacts with side chains from
lobe II (Fig. 4A). As shown in Fig. 4B, glutamate
may adopt a similar orientation, lying across rather than along the
cleft, enabling it to interact with both sides in the absence of a
dramatic closure. The
-amino group bound deep within the cleft is
also positioned so that only small rearrangements are apparently
required to enable the recruitment of Glu706 into a
hydrogen-bonding network that spans both lobes and the agonist. This
explains how agonists could be capable of linking the lobes of S1S2
together utilizing only subtle conformational changes within the
domain. These small motions can then trigger subsequent conformational
changes that open and close the channel pore. There is precedent for
such subtlety both among the repressor protein-binding domains, whose
conformational changes appear restricted by the need to maintain
oligomeric interactions (31), and among PBP involved in transport
(30, 59).
 |
ACKNOWLEDGEMENTS |
We thank U. Reygers for skillful technical
assistance. We thank M. Geeves (Max Planck Institute for Molecular
Physiology, Dortmund, Germany) for the pressure-jump experiments. We
thank J. Reinstein (Max Planck Institute for Molecular Physiology,
Dortmund) and J. Wray for suggestions on improving the manuscript.
 |
FOOTNOTES |
*
This work was supported by the Departments of Biophysics and
Cell Physiology at the Max Planck Institute for Medical Research, European Union Fourth Framework Program in Biotechnology Grant BIO4-CT96-0589 (to D. R. M. and K. K.), and by the Academy of Finland (to K. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Inst. for Physiological Chemistry,
Phillips-Universität Marburg, Karl-v.-Frisch-Str. 1, 35043 Marburg, Germany.
To whom correspondence should be addressed. Tel.:
49-6221-486150; Fax: 49-6221-486437; E-mail:
madden@mpimf-heidelberg.mpg.de.
Published, JBC Papers in Press, March 28, 2000, DOI 10.1074/jbc.M909883199
2
M. Safferling, K. Keinänen, and D. R. Madden, unpublished data.
3
R. Abele and M. Geeves, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
GluR, glutamate
receptor ion channel(s);
AMPA,
-amino-3-hydroxy-5-methyl-4-isoxazole
propionate;
PBP, periplasmic binding protein(s);
QBP, glutamine-binding
protein.
 |
REFERENCES |
| 1.
|
Nakanishi, S.
(1992)
Science
258,
597-603
|
| 2.
|
Sommer, B.,
and Seeburg, P. H.
(1992)
Trends Neurosci.
13,
291-296
|
| 3.
|
Keinänen, K.,
Wisden, W.,
Sommer, B.,
Werner, P.,
Herb, A.,
Verdoorn, T. A.,
Sakmann, B.,
and Seeburg, P. H.
(1990)
Science
249,
556-560
|
| 4.
|
Hollmann, M.,
and Heinemann, S.
(1994)
Annu. Rev. Neurosci.
17,
31-108
|
| 5.
|
Colquhoun, D.,
Jonas, P.,
and Sakmann, B.
(1992)
J. Physiol. (Lond.)
458,
261-287
|
| 6.
|
Seeburg, P. H.
(1993)
Trends Neurosci.
16,
359-365
|
| 7.
|
Kiskin, N. I.,
Krishtal, O. A.,
and Tsyndrenko, A.
(1986)
Neurosci. Lett.
63,
225-230
|
| 8.
|
Mayer, M. L.,
and Vyklicky, L., Jr.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1411-1415
|
| 9.
|
Tang, C. M.,
Dichter, M.,
and Morad, M.
(1989)
Science
243,
1474-1477
|
| 10.
|
Vyklicky, L. J.,
Patneau, D. K.,
and Mayer, M. L.
(1991)
Neuron
7,
971-984
|
| 11.
|
Trussell, L. O.,
Zhang, S.,
and Raman, I. M.
(1993)
Neuron
10,
1185-1196
|
| 12.
|
Yamada, K. A.,
and Tang, C. M.
(1993)
J. Neurosci.
13,
3904-3915
|
| 13.
|
Larson, J.,
Le, T. T.,
Hall, R. A.,
and Lynch, G.
(1994)
Neuroreport
5,
389-392
|
| 14.
|
Stern-Bach, Y.,
Bettler, B.,
Hartley, M.,
Sheppard, P. O.,
O'Hara, P. J.,
and Heinemann, S. F.
(1994)
Neuron
13,
1345-1357
|
| 15.
|
Miyazawa, A.,
Fujiyoshi, Y.,
Stowell, M.,
and Unwin, N.
(1999)
J. Mol. Biol.
288,
765-786
|
| 16.
|
Colquhoun, D.,
and Sakmann, B.
(1998)
Neuron
20,
381-387
|
| 17.
|
Kuusinen, A.,
Arvola, M.,
and Keinänen, K.
(1995)
EMBO J.
14,
6327-6332
|
| 18.
|
O'Hara, P. J.,
Sheppard, P. O.,
Thogersen, H.,
Venezia, D.,
Haldeman, B. A.,
McGrane, V.,
Houamed, K. M.,
Thomsen, C.,
Gilbert, T. L.,
and Mulvihill, E. R.
(1993)
Neuron
11,
41-52
|
| 19.
|
Wo, Z. G.,
and Oswald, R. E.
(1995)
Trends Neurosci.
18,
161-168
|
| 20.
|
Nakanishi, N.,
Schneider, N. A.,
and Axel, R.
(1990)
Neuron
5,
569-581
|
| 21.
|
Armstrong, N.,
Sun, Y.,
Chen, G.-Q.,
and Gouaux, J. E.
(1998)
Nature
395,
913-916
|
| 22.
|
Shilton, B. H.,
Flocco, M. M.,
Nilsson, M.,
and Mowbray, S. L.
(1996)
J. Mol. Biol.
264,
350-363
|
| 23.
|
Newcomer, M. E.,
Lewis, B. A.,
and Quiocho, F. A.
(1981)
J. Biol. Chem.
256,
13218-13222
|
| 24.
|
Olah, G. A.,
Trakhanov, S.,
Trewhella, J.,
and Quiocho, F. A.
(1993)
J. Biol. Chem.
268,
16241-16247
|
| 25.
|
Oh, B. H.,
Pandit, J.,
Kang, C. H.,
Nikaido, K.,
Gokcen, S.,
Ames, G. F. L.,
and Kim, S. H.
(1993)
J. Biol. Chem.
268,
11348-11355
|
| 26.
|
Sack, J. S.,
Saper, M. A.,
and Quiocho, F. A.
(1989)
J. Mol. Biol.
206,
171-191
|
| 27.
|
Mao, B.,
Pear, M. R.,
McCammon, J. A.,
and Quiocho, F. A.
(1982)
J. Biol. Chem.
257,
1131-1133
|
| 28.
|
Laube, B.,
Hirai, H.,
Sturgess, M.,
Betz, H.,
and Kuhse, J.
(1997)
Neuron
18,
493-503
|
| 29.
|
Mano, I.,
Lamed, Y.,
and Teichberg, V. I.
(1996)
J. Biol. Chem.
271,
15299-15302
|
| 30.
|
Sharff, A. J.,
Rodseth, L. E.,
and Quiocho, F. A.
(1993)
Biochemistry
32,
10553-10559
|
| 31.
|
Mowbray, S. L.,
and Björkman, A. J.
(1999)
J. Mol. Biol.
294,
487-499
|
| 32.
|
Patneau, D. K.,
Vyklicky, L., Jr.,
and Mayer, M. L.
(1993)
J. Neurosci.
13,
3496-3509
|
| 33.
|
Abele, R.,
Svergun, D.,
Keinänen, K.,
Koch, M. J. H.,
and Madden, D. R.
(1999)
Biochemistry
38,
10949-10957
|
| 34.
|
Abele, R.
(1998)
Biochemische und Biophysikcalische Charakterisiervng Extrazellulärer Fragmente der Ionotropen Glutamatrezeptoruntereinheit GluRD.Ph.D. thesis
, Ruprecht-Karls-Universität, Heidelberg, Germany
|
| 35.
|
Ledvina, P. S.,
Tsai, A.-L.,
Wang, Z.,
Koehl, E.,
and Quiocho, F. A.
(1998)
Protein Sci.
7,
2550-2559
|
| 36.
|
Vermersch, P. S.,
Tesmer, J. J. G.,
Lemon, D. D.,
and Quiocho, F. A.
(1990)
J. Biol. Chem.
265,
16592-16603
|
| 37.
|
Abele, R.,
Lampinen, M.,
Keinänen, K.,
and Madden, D. R.
(1998)
J. Biol. Chem.
273,
25132-25138
|
| 38.
|
Lampinen, M.,
Pentikäinen, O.,
Johnson, M. S.,
and Keinänen, K.
(1998)
EMBO J.
17,
4704-4711, and references therein
|
| 39.
|
Hiromi, K.
(1979)
Kinetics of Fast Enzyme Reactions
, pp. 187-286, Halsted Press, New York
|
| 40.
|
Wallace, A. C.,
Laskowski, R. A.,
and Thornton, J. M.
(1995)
Protein Eng.
8,
127-134
|
| 41.
|
Jones, T. A.,
Zou, J.-Y.,
and Cowan, S. W.
(1991)
Acta Crystallogr. Sect. A
47,
110-119
|
| 42.
|
Ponder, J. W.,
and Richards, F. M.
(1987)
J. Mol. Biol.
193,
775-791
|
| 43.
|
Weiner, J. H.,
and Heppel, L. A.
(1971)
J. Biol. Chem.
246,
6933-6941
|
| 44.
|
Miller, D. M., III,
Olson, J. S.,
Pflugrath, J. W.,
and Quiocho, F. A.
(1983)
J. Biol. Chem.
258,
13665-13672
|
| 45.
|
Clements, J. D.,
Feltz, A.,
Sahara, Y.,
and Westbrook, G. L.
(1998)
J. Neurosci.
18,
119-127
|
| 46.
|
Lester, R. A. J.,
Tong, G.,
and Jahr, C. E.
(1993)
J. Neurosci.
13,
1088-1096
|
| 47.
|
Arai, A.,
Silberg, J.,
Kessler, M.,
and Lynch, G.
(1995)
Neuroscience
66,
815-827
|
| 48.
|
Jayaraman, V.
(1998)
Biochemistry
37,
16735-16740
|
| 49.
|
Uchino, S.,
Sakimura, K.,
Nagahari, K.,
and Mishina, M.
(1992)
FEBS Lett.
308,
252-257
|
| 50.
|
Paas, Y.,
Eisenstein, M.,
Medevielle, F.,
Teichberg, V. I.,
and Devillers-Thiery, A.
(1996)
Neuron
17,
979-990
|
| 51.
|
Hirai, H.,
Kirsch, J.,
Laube, B.,
Betz, H.,
and Kuhse, J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6031-6036
|
| 52.
|
Wafford, K. A.,
Kathoria, M.,
Bain, C. J.,
Marshall, G.,
Le Bourdelles, B.,
Kemp, J. A.,
and Whiting, P. J.
(1995)
Mol. Pharmacol.
47,
374-380
|
| 53.
|
Kawamoto, S.,
Uchino, S.,
Xin, K.-Q.,
Hattori, S.,
Hamajima, K.,
Fukushima, J.,
Mishina, M.,
and Okuda, K.
(1997)
Mol. Brain Res.
47,
339-344
|
| 54.
|
Williams, K.,
Chao, J.,
Kashiwagi, K.,
Masuko, T.,
and Igarashi, K.
(1996)
Mol. Pharmacol.
50,
701-708
|
| 55.
|
Walmsley, A. R.,
Shaw, J. G.,
and Kelly, D. J.
(1992)
J. Biol. Chem.
267,
8064-8072
|
| 56.
|
Saper, M. A.,
and Quiocho, F. A.
(1983)
J. Biol. Chem.
258,
11057-11062
|
| 57.
|
Yao, N. H.,
Trakhanov, S.,
and Quicho, F. A.
(1994)
Biochemistry
33,
4769-4779
|
| 58.
|
Sun, Y.-J.,
Rose, J.,
Wang, B.-C.,
and Hsiao, C.-D.
(1998)
J. Mol. Biol.
278,
219-229
|
| 59.
|
Lawrence, M. C.,
Pilling, P. A.,
Epa, V. C.,
Berry, A. M.,
Ogunniyi, A. D.,
and Paton, J. C.
(1998)
Structure
6,
1553-1561
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Oswald, S. H. J. Smits, M. Hoing, L. Sohn-Bosser, L. Dupont, D. Le Rudulier, L. Schmitt, and E. Bremer
Crystal Structur |